Zina Chatzidimitriadou

Senior Managing Associate, Sidley Austin

ZINA CHATZIDIMITRIADOU advises life sciences and medtech clients on all aspects of product lifecycle management under UK and EU law. A former scientist, having worked in molecular biology research, Zina brings with her the ability to effectively understand the science. She has a particular focus on advising and speaking on regulatory protections and IP rights, cell and gene therapies, market access, digital health, and artificial intelligence.

Zina’s practice covers the pharmaceutical, medical device, medtech, biotechnology, food, cosmetics, and novel products (such as cannabidiol or CBD) industries on both advisory and contentious matters. Zina also co-leads the industry benchmarking group, ctlegal, for clinical trials in the pharmaceutical industry.

Contributed to

2

Conducting clinical research—data protection implications

Practice Notes

This Practice Note explores the data protection implications of conducting clinical research. In particular, this Practice Note considers the responsibility for data protection compliance in the context of clinical research, the relevant legal grounds for processing personal data for research purposes, transparency requirements, collaborative research and data sharing as well as exceptions to data subject rights when processing personal data in the context of research. Finally, this Practice Note provides a checklist of practical data protection considerations to bear in mind when planning research activities.

Life Sciences

Coronavirus (COVID-19)—regulatory implications for the UK and European life sciences industry [Archived]

Practice Notes

This Practice Note has been archived and is not maintained. It discusses the regulatory implications of the coronavirus (COVID-19) pandemic for the UK and European life sciences industry. It provides guidance as to the response of UK and EU regulators in the areas of clinical trials, inspections and the continuity of supply in medicinal products and medical devices, as well as the postponement of implementation of the Medical Devices Regulation (MDR). It also summarises key research and development (R&D) initiatives at a UK and EU level and European Commission guidance on the collection and transfusion of convalescent COVID-19 plasma.

Life Sciences